Skip to content

Author

L. Spadafora

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions

Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...

P. Sabouret, D. Giamundo, J. Popiołek-Kalisz et al. · 0 citations
Review Open access Aug 2026

Cardiovascular risk management in the elderly: a dilemma in daily clinical practice.

Cardiovascular disease is the leading cause of morbidity and mortality in the elderly. Managing cardiovascular risk in this group is uniquely challenging due to physiological changes, multimorbidity, polypharmacy, and frailty, compounded by the under-representation of older adults in clinical trials Recent advances, in...

G. Dacquino, G. Galati, Luca Genovese et al. · 0 citations
Review Aug 2026

Sacubitril/valsartan in anthracycline-treated patients: a systematic review and meta-analysis of available evidence

Anthracyclines remain a cornerstone of systemic anticancer therapy but are limited by their well-recognized cardiotoxic potential, which may manifest as cancer therapy–related cardiac dysfunction (CTRCD). Despite increasing emphasis on preventive strategies in cardio-oncology, robust evidence supporting pharmacol...

M. Camilli, L. Spadafora · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.